Literature DB >> 15753007

The papillomavirus life cycle.

John Doorbar1.   

Abstract

Papillomaviruses infect epithelial cells, and depend on epithelial differentiation for completion of their life cycle. The expression of viral gene products is closely regulated as the infected basal cell migrates towards the epithelial surface. Expression of E6 and E7 in the lower epithelial layers drives cells into S-phase, which creates an environment that is conducive for viral genome replication and cell proliferation. Genome amplification, which is necessary for the production of infectious virions, is prevented until the levels of viral replication proteins rise, and depends on the co-expression of several viral proteins. Virus capsid proteins are expressed in cells that also express E4 as the infected cell enters the upper epithelial layers. The timing of these events varies depending on the infecting papillomavirus, and in the case of the high-risk human papillomaviruses (HPVs), on the severity of neoplasia. Viruses that are evolutionarily related, such as HPV1 and canine oral papillomavirus (COPV), generally organize their productive cycle in a similar way, despite infecting different hosts and epithelial sites. In some instances, such as following HPV16 infection of the cervix or cottontail rabbit papillomavirus (CRPV) infection of domestic rabbits, papillomaviruses can undergo abortive infections in which the productive cycle of the virus is not completed. As with other DNA tumour viruses, such abortive infections can predispose to cancer.

Entities:  

Mesh:

Year:  2005        PMID: 15753007     DOI: 10.1016/j.jcv.2004.12.006

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  232 in total

Review 1.  Vocal fold epithelial barrier in health and injury: a research review.

Authors:  Elizabeth Erickson Levendoski; Ciara Leydon; Susan L Thibeault
Journal:  J Speech Lang Hear Res       Date:  2014-10       Impact factor: 2.297

2.  Heterogeneous Nuclear Ribonucleoprotein C Proteins Interact with the Human Papillomavirus Type 16 (HPV16) Early 3'-Untranslated Region and Alleviate Suppression of HPV16 Late L1 mRNA Splicing.

Authors:  Soniya Dhanjal; Naoko Kajitani; Jacob Glahder; Ann-Kristin Mossberg; Cecilia Johansson; Stefan Schwartz
Journal:  J Biol Chem       Date:  2015-04-15       Impact factor: 5.157

Review 3.  Prevention of cancer by prophylactic human papillomavirus vaccines.

Authors:  Kihyuck Kwak; Anna Yemelyanova; Richard B S Roden
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

4.  Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator.

Authors:  Noor Gammoh; Helena Sterlinko Grm; Paola Massimi; Lawrence Banks
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Novel papillomavirus isolates from Erinaceus europaeus (Erinaceidae, Insectivora) and the Cervidae (Artiodactyla), Cervus timorensis and Pudu puda, and phylogenetic analysis of partial sequence data.

Authors:  Marc Gottschling; Gudrun Wibbelt; Ulrich Wittstatt; Eggert Stockfleth; Ingo Nindl
Journal:  Virus Genes       Date:  2008-01-22       Impact factor: 2.332

6.  Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.

Authors:  Carolina Scagnolari; Fabiana Cannella; Alessandra Pierangeli; Rebecca Mellinger Pilgrim; Guido Antonelli; Dayana Rowley; Margaret Wong; Simon Best; Deyin Xing; Richard B S Roden; Raphael Viscidi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

Review 7.  Role of plasmonics in detection of deadliest viruses: a review.

Authors:  Foozieh Sohrabi; Sajede Saeidifard; Masih Ghasemi; Tannaz Asadishad; Seyedeh Mehri Hamidi; Seyed Masoud Hosseini
Journal:  Eur Phys J Plus       Date:  2021-06-20       Impact factor: 3.911

Review 8.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  Genetic analysis of the E2 transactivation domain dimerization interface from bovine papillomavirus type 1.

Authors:  David Gagnon; Hélène Sénéchal; Claudia M D'Abramo; Jennifer Alvarez; Alison A McBride; Jacques Archambault
Journal:  Virology       Date:  2013-03-11       Impact factor: 3.616

10.  Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

Authors:  John T Schiller; Douglas R Lowy
Journal:  J Infect Dis       Date:  2009-07-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.